CN1671398A - 治疗上皮和视网膜组织疾病的组合物和方法 - Google Patents

治疗上皮和视网膜组织疾病的组合物和方法 Download PDF

Info

Publication number
CN1671398A
CN1671398A CNA038040085A CN03804008A CN1671398A CN 1671398 A CN1671398 A CN 1671398A CN A038040085 A CNA038040085 A CN A038040085A CN 03804008 A CN03804008 A CN 03804008A CN 1671398 A CN1671398 A CN 1671398A
Authority
CN
China
Prior art keywords
disease
group
benzyl
methylene
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038040085A
Other languages
English (en)
Chinese (zh)
Inventor
B·R·叶克沙
J·G·道格拉斯三世
S·R·谢弗
W·M·彼德森
E·G·布朗
C·S·克里恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of CN1671398A publication Critical patent/CN1671398A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNA038040085A 2002-02-27 2003-02-27 治疗上皮和视网膜组织疾病的组合物和方法 Pending CN1671398A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/082,998 US7115585B2 (en) 2000-08-21 2002-02-27 Compositions for treating epithelial and retinal tissue diseases
US10/082,998 2002-02-27

Publications (1)

Publication Number Publication Date
CN1671398A true CN1671398A (zh) 2005-09-21

Family

ID=27765292

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038040085A Pending CN1671398A (zh) 2002-02-27 2003-02-27 治疗上皮和视网膜组织疾病的组合物和方法

Country Status (12)

Country Link
US (1) US7115585B2 (OSRAM)
EP (2) EP2647382A1 (OSRAM)
JP (1) JP4745610B2 (OSRAM)
KR (1) KR100990346B1 (OSRAM)
CN (1) CN1671398A (OSRAM)
AR (1) AR038612A1 (OSRAM)
AU (1) AU2003223225B2 (OSRAM)
BR (1) BR0307783A (OSRAM)
CA (1) CA2477241C (OSRAM)
MX (1) MXPA04008293A (OSRAM)
TW (1) TW200408399A (OSRAM)
WO (1) WO2003072067A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103339136A (zh) * 2010-12-01 2013-10-02 巴伊兰大学 尿苷二-或三-磷酸衍生物以及其用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
US7741473B2 (en) * 2005-03-30 2010-06-22 Inspire Pharmaceuticals, Inc. Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN103429605B (zh) * 2011-01-26 2017-11-07 北京康倍得医药技术开发有限公司 呋喃核糖基嘌呤类化合物及其制备方法和应用
WO2014060941A2 (en) * 2012-10-17 2014-04-24 Mahesh Kandula Compositions and methods of neuroprotective agents for the treatment of neurological and neurodegenerative diseases
KR102883682B1 (ko) 2016-02-18 2025-11-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
MX2019013363A (es) * 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
EP3746134A1 (en) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
US10946034B2 (en) 2018-03-27 2021-03-16 Invirsa, Inc. Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
EP3849992A4 (en) 2018-09-11 2022-06-29 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321462A (en) * 1963-07-15 1967-05-23 Syntex Corp Process for the preparation of nucleoside polyphosphates
US3324110A (en) * 1965-02-05 1967-06-06 Schering Corp Method of phosphorylation and novel intermediates produced thereby
JPS509872B1 (OSRAM) * 1969-12-22 1975-04-16
JPS5427582A (en) * 1977-08-02 1979-03-01 Mitsubishi Chem Ind Ltd Preparation of dinucleoside triphosphate
JPS5427581A (en) * 1977-08-02 1979-03-01 Mitsubishi Chem Ind Ltd P1-s-phenylthiop2-nucleoside 5'-pyrophosphates and their preparation
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
US4710566A (en) * 1984-12-27 1987-12-01 Yale University Purification of the messenger RNA cap-binding protein
GB8529684D0 (en) * 1985-12-02 1986-01-08 Medical Res Council Photo-labile protecting agents
JPS62265299A (ja) * 1985-12-18 1987-11-18 Senjiyu Seiyaku Kk α―トコフェロールとウリジンとのリン酸ジエステル，そのハロゲン置換体もしくはこれらの塩およびそれらの製造法
AU1790988A (en) * 1987-05-19 1988-12-21 Baylor College Of Medicine Phosphoethanolamine for treatment of alzheimer's disease
EP0508687B1 (en) 1991-04-06 1995-09-13 Astra Pharmaceuticals Limited ATP analogues
US5654285A (en) * 1991-04-06 1997-08-05 Astra Pharmaceuticals Limited ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
PL175623B1 (pl) 1993-02-10 1999-01-29 Astra Pharma Prod N-alkilo-2-podstawione analogi ATP, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca
US5444541A (en) * 1994-02-16 1995-08-22 Eastern Washington University Methods for photoacoustically analyzing chemicals and chemical reactions using photoactive particle-emitting compounds
US5536822A (en) * 1994-03-09 1996-07-16 University Of Virginia Alumni Patents Foundation γ-phosphate linked adenosine 5' triphosphate sepharose
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
TW427996B (en) * 1995-07-11 2001-04-01 Astra Pharma Prod Novel triazolopyrimidines and their use as medicaments
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6319908B1 (en) * 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
JP2001504097A (ja) * 1996-10-30 2001-03-27 ザ・ユニヴァーシティ・オブ・ノース・キャロライナ・アト・チャペル・ヒル Ｐ２ｙレセプターアンタゴニスト
WO1998028300A1 (en) 1996-12-20 1998-07-02 Astra Pharmaceuticals Ltd. Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments
NZ337225A (en) * 1997-02-06 2002-03-28 Inspire Pharmaceuticals Inc Dinucleotides useful for treating chronic pulmonary obstructive disorder
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
SE9702774D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
CA2332540A1 (en) * 1998-05-22 1999-12-02 Benjamin R. Yerxa Therapeutic dinucleotide and derivatives
US6451568B1 (en) * 1998-06-08 2002-09-17 Dalhousie University Cloning of human choline ethanolaminephospho transferases synthesis of phosphatidyl choline phosphatidyle thanolamine and platelet activating factor
SE9804175D0 (sv) 1998-12-02 1998-12-02 Astra Pharma Prod New assay
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
US6399335B1 (en) * 1999-11-16 2002-06-04 Advanced Research And Technology Institute, Inc. γ-phosphoester nucleoside triphosphates
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
CA2328684A1 (en) * 2000-12-15 2002-06-15 Yahia Gawad Photon-triggered luminescent assay

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103339136A (zh) * 2010-12-01 2013-10-02 巴伊兰大学 尿苷二-或三-磷酸衍生物以及其用途

Also Published As

Publication number Publication date
BR0307783A (pt) 2005-09-13
EP1545555A4 (en) 2010-09-29
EP2647382A1 (en) 2013-10-09
WO2003072067A2 (en) 2003-09-04
KR100990346B1 (ko) 2010-10-29
TW200408399A (en) 2004-06-01
JP2005526046A (ja) 2005-09-02
EP1545555A2 (en) 2005-06-29
US20030008834A1 (en) 2003-01-09
AU2003223225A1 (en) 2003-09-09
CA2477241A1 (en) 2003-09-04
WO2003072067A3 (en) 2005-04-28
CA2477241C (en) 2012-04-10
AU2003223225B2 (en) 2007-02-22
MXPA04008293A (es) 2004-11-26
JP4745610B2 (ja) 2011-08-10
KR20040094736A (ko) 2004-11-10
US7115585B2 (en) 2006-10-03
AR038612A1 (es) 2005-01-19

Similar Documents

Publication Publication Date Title
CN1262556C (zh) 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用
CN1671398A (zh) 治疗上皮和视网膜组织疾病的组合物和方法
CN1042430C (zh) N－烷基－2－取代的atp类似物、其制备方法和用途
US6323187B1 (en) Therapeutic dinucleotide and derivatives
JP4923216B2 (ja) 化合物
US8163707B2 (en) 4′-allene-substituted nucleoside derivatives
CN1501940A (zh) 抑制血小板聚集的组合物和方法
US20130078217A1 (en) 2'-chloroacetylenyl substituted nucleoside derivatives
CN1033183A (zh) 氟胞嘧啶核苷衍生物
WO2012125900A1 (en) 2'-allene-substituted nucleoside derivatives
WO2003072066A2 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
US7612047B2 (en) Degradation-resistant mononucleoside phosphate compounds
US6555675B2 (en) Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
JP2005526046A5 (OSRAM)
CN1612739A (zh) 治疗或预防炎性疾病的方法
US6867199B2 (en) Dinucleoside polyphosphate compositions and their therapeutic use
JP2018503606A (ja) 生体可逆性ジスルフィド基を有するモノヌクレオチド
IE921083A1 (en) Substituted 2',3'-dideoxy-5-trifluoromethyluridines,¹processes for their preparation and their use in medicaments
CN1780631A (zh) 抗癌膦酸酯类似物
HK1033464A (en) Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication